Glaxo Diabetes Drug Will Face SB's Avandia; Anti-Herpetic Divestment Likely

21 Feb 2000

• By The Pink Sheet

Glaxo Wellcome intends to compete in the diabetes market with SmithKline Beecham's Avandia, Glaxo Chairman Richard Sykes indicated at an analysts earnings conference Feb. 16.

Glaxo Diabetes Drug Will Face SB's Avandia; Anti-Herpetic Divestment Likely

More from Archive

More from Pink Sheet